WJ-39

• Description :

  WJ-39 is an orally active aldose reductase (AR) inhibitor that ameliorates renal lesions in diabetic nephropathy through activation of Nrf2 signaling, and may be used to ameliorate renal insufficiency and fibrosis.WJ-39 inhibits oxidative stress and inhibits the activation of the inflammatory vesicle of the oligomerization structural domain-like receptor family, pyrin structural domain 3 (NLRP3) .

• Stability :

  ≥ 2 years

• Purity :

  >98% (HPLC)

• Weight :

  430.32

• Molecular Formula :

  C19H14Cl2KNO4

• Notes :

  Research use only, not for human use.

• Receptor :

  Reductase

• CAS Number :

  3009908-95-3